Wednesday, October 28, 2009
Parexel’s first quarter consolidated service revenue dipped 1.2% to $259.8 million, compared with $263 million in the prior year period. Net income also slipped to $12.4 million, or $0.21 per diluted share, compared with net income of $13.6 million, or $0.23 per diluted share, for the year ago quarter.
The Oncology R&D unit of GlaxoSmithKline (GSK) has entered into a new research alliance agreement with US Oncology, a nationwide cancer care company that supports a community-based research network specializing in phase I through IV oncology clinical trials. The non-exclusive collaboration is aimed at improving the execution time of GSK’s oncology clinical trials.